Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.

Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog. - Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035193

Enrollment

100

Registered

2018-12-10

Start date

2018-12-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma or ocular hypertension

Interventions

Switching from Prostaglandin analog to Eybelis ophthalmic solution 0.002%

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unilateral or bilateral primary open angle glaucoma or ocular hypertension Patients with some deepening of upper eyelid sulcus after topical use of prostaglandin analogs good adherence before the study initiation

Exclusion criteria

Exclusion criteria: Patients with aphakic eye or implanted IOL in the eye (history of cataract surgery), Patients with cataract surgery scheduled (within the last 6 months) Patients with some corneal abnormality or other diseases which may interfere with accurate IOP measurement using Goldmann applanation tonometer Patients with a history of corneal refractive surgery Patients with active extraocular disease, inflammation or infection in the eye(s) or eyelid(s) Patients with allergy to the ingredients used in the present study Pregnant, lactating women or women who may be pregnant, and women who wish to be pregnant or can not conduct appropriate contraception during the study period

Design outcomes

Primary

Measure	Time frame
IOP reduction Adverse event	—

Secondary

Measure	Time frame
Feeling of use	—

Countries

Japan

Contacts

Public ContactKenji Inoue

Inouye Eye Hospital Medical office

study@inouye-eye.or.jp03-3295-0911

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026